ZELMAC ® 6 mg tabletsPresentation: Tegaserod. Tablets: 6 mg tegaserod as hydrogen maleate. Indications/Potential uses: Symptomatictreatment of female patients with abdominal pain and constipation associated with irritable bowel syndrome. An organ-ic origin of such symptoms must be ruled out by means of appropriate investigations. Dosage: 6 mg twice daily priorto a meal for a maximum of 12 weeks. Contraindications: Hypersensitivity to tegaserod hydrogen maleate and/or toany of the excipients. Precautions: Diarrhoea and/or patients with recurrent diarrhoea associated with IBS. Caution isrequired in patients in whom increased gastrointestinal motility could have negative effects. Use of Zelmac cannot berecommended in patients with severe hepatic impairment or severe renal failure. Caution is required in patients withmild to moderately severe renal or hepatic failure. Interactions: No drug interactions of clinical relevance. Adversereactions: The overall incidence of adverse events in clinical trials was comparable with that of placebo, with excep-tion of diarrhoea. Packs and prices: Country-specific. Note: Before prescribing, please read full product information.

References:1. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force. Evidence-based position statement on

the management of irritable bowel syndrome. Am J Gastroenterol. 2002;97 (suppl):S1-S27.2. Data on file, Annotated Package insert. a Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.3. Schmitt C, et al. The 5HT4 partial agonist, tegaserord, a partial 5H4 agonist improves abdominal/pain and altered bowel function

in irritable bowel syndrome. Gut 1999;45 (Suppl.V):A2604. Muller-Lissner SA, et al. Tegaserod , a 5 HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with

abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001,15:1655-16665. Novick J, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel

syndrome with constipation. Aliment Pharmacol Ther 2002; 16:1877-1888

ZE

L D

F 0

1/04

ME

+ A

e